{"clinical_study": {"@rank": "141", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 02, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04255017"}, "id_info": {"org_study_id": "TJ20200128", "nct_id": "NCT04255017"}, "brief_title": "A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia", "official_title": "An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.", "sponsors": {"lead_sponsor": {"agency": "Tongji Hospital", "agency_class": "Other"}}, "source": "Tongji Hospital", "oversight_info": {"is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "At present, there is no specific and effective antiviral therapy.In this study, an open,\n      prospective/retrospective, randomized controlled cohort study was designed to compare the\n      efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the\n      efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of\n      2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To\n      provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by\n      new coronavirus infection."}, "overall_status": "Recruiting", "start_date": {"@type": "Actual", "#text": "February 1, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "July 1, 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "June 1, 2020"}, "phase": "Phase 4", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Treatment", "masking": "Single (Participant)"}, "primary_outcome": [{"measure": "Rate of disease remission", "time_frame": "two weeks", "description": "A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2> 93% or PaO2/FiO2>300mmHg (1mmHg=0.133Kpa);"}, {"measure": "Time for lung recovery", "time_frame": "two weeks", "description": "Compare the average time of lung imaging recovery after 2 weeks of treatment in each group."}], "secondary_outcome": [{"measure": "Rate of no fever", "time_frame": "two weeks"}, {"measure": "Rate of respiratory symptom remission", "time_frame": "two weeks"}, {"measure": "Rate of lung imaging recovery", "time_frame": "two weeks"}, {"measure": "Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery", "time_frame": "two weeks"}, {"measure": "Rate of undetectable viral RNA", "time_frame": "two weeks"}], "number_of_arms": "4", "enrollment": {"@type": "Anticipated", "#text": "400"}, "condition": "2019-nCoV", "arm_group": [{"arm_group_label": "Symptomatic supportive treatment", "arm_group_type": "No Intervention", "description": "Symptomatic supportive treatment"}, {"arm_group_label": "Abidol hydrochloride was added on the basis of group I.", "arm_group_type": "Experimental", "description": "Abidol hydrochloride 0.2g once,3 times a day,2 weeks"}, {"arm_group_label": "Oseltamivir was added on the basis of group I.", "arm_group_type": "Experimental", "description": "Oseltamivir 75mg once,twice a day,2 weeks"}, {"arm_group_label": "Lopinavir/ritonavir was added on the basis of group I.", "arm_group_type": "Experimental", "description": "Lopinavir/ritonavir 500mg once,twice a day,2 weeks"}], "intervention": [{"intervention_type": "Drug", "intervention_name": "Abidol hydrochloride", "description": "Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.", "arm_group_label": "Abidol hydrochloride was added on the basis of group I."}, {"intervention_type": "Drug", "intervention_name": "Oseltamivir", "description": "Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.", "arm_group_label": "Oseltamivir was added on the basis of group I."}, {"intervention_type": "Drug", "intervention_name": "Lopinavir/ritonavir", "description": "Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.", "arm_group_label": "Lopinavir/ritonavir was added on the basis of group I."}], "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          1. 2019-nCoV nucleic acid test was positive.\n\n          2. CT of the lung conformed to the manifestation of viral pneumonia.\n\n        Exclusion Criteria:\n\n          1. Patients who meet any of the contraindications in the experimental drug labeling\n\n          2. Patients who do not want to participate in this clinical study"}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No"}, "overall_contact": {"last_name": "Qing Ning, Professor", "phone": "+8613971521450", "email": "qning@vip.sina.com"}, "overall_contact_backup": {"last_name": "Meifang Han, Professor", "phone": "+8613986093605", "email": "mfhan@foxmail.com"}, "location": {"facility": {"name": "Department and Institute of Infectious Disease", "address": {"city": "Wuhan", "state": "Hubei", "zip": "430030", "country": "China"}}, "status": "Recruiting", "contact": {"last_name": "Qin Ning, professor", "email": "qning@vip.sina.com"}, "contact_backup": {"last_name": "Meifang Han, professor", "email": "mfhan@foxmail.com"}}, "location_countries": {"country": "China"}, "verification_date": "March 2020", "study_first_submitted": "February 2, 2020", "study_first_submitted_qc": "February 2, 2020", "study_first_posted": {"@type": "Actual", "#text": "February 5, 2020"}, "last_update_submitted": "March 14, 2020", "last_update_submitted_qc": "March 14, 2020", "last_update_posted": {"@type": "Actual", "#text": "March 17, 2020"}, "responsible_party": {"responsible_party_type": "Principal Investigator", "investigator_affiliation": "Tongji Hospital", "investigator_full_name": "Qin Ning", "investigator_title": "Professor"}, "condition_browse": {"mesh_term": "Pneumonia"}, "intervention_browse": {"mesh_term": ["Ritonavir", "Lopinavir", "Oseltamivir", "Antiviral Agents"]}, "patient_data": {"sharing_ipd": "Undecided"}}}